Advertisement

NanoEthics

, Volume 2, Issue 1, pp 87–97 | Cite as

European Regulatory Issues in Nanomedicine

  • Giorgia Guerra
Original paper

Abstract

The paper is intended to focus on peculiarities of nanomedicine and the importance of social concerns implicated, in order to understand if existing regulations are appropriate to maintain its safety or if a new ad hoc regulatory framework is needed. Consideration of social challenges will underline the crucial role of medical ethics in regulatory discussion.

Keywords

Nanomedicine Medical ethics Technology regulation Risk perception 

References

  1. 1.
    Abbott KW, Marchant, GE, Sylvester DJ (2006) A framework convention for nanotechnology? Environ Law Report 36 (article 777). http://ssrn.com/abstract=946777
  2. 2.
    Bayiley, R Rebels (2004) Against the future: witnessing the birth of the global anti-technology movement (Reason Online). http://reason.com/rb/rb022801.html. Cited October 2006
  3. 3.
    Beck U (2000) La società del rischio. Verso una nuova modernità (Italian version). Carocci, RomaGoogle Scholar
  4. 4.
    Berenghi A (1992) In merito alla responsabilità del produttore, importatore e fornitore di farmaci dannosi per la salute. Nuova giur civ 569Google Scholar
  5. 5.
    Best R, Khushf G (2006) Symposium article: ethical and social issues integral to the development of specific initiatives in nanotechnology: the social conditions for nanomedicine: disruption, systems, and lock-in. J Law Med Ethics 34:733CrossRefGoogle Scholar
  6. 6.
    Bucchi M (2006) Scegliere il mondo che vogliamo. Cittadini, politica, tecnoscienza. il Mulino, BolognaGoogle Scholar
  7. 7.
    Carnevali U (2006) Consegna del prodotto al distributore e “messa in commercio” di esso. Resp civ e prev, 831Google Scholar
  8. 8.
    Castel R (1991) From dangerousness to risk. In: Burchell G, Gordon G, Miller P (eds) The Foucault effect: studies in governmentality. University of Chicago Press, ChicagoGoogle Scholar
  9. 9.
    Chai JY (2000) Medical device regulation in the United States and the European Union: a comparative study. Food Drug Law J 55:57–80Google Scholar
  10. 10.
    Foote SB, Berlin RJ (2005) Can regulation be as innovative as science and technology? The FDA’s regulation of combination products. Minn J Law Sci Tech 6:619Google Scholar
  11. 11.
    Horton LR (1993) Over the Counter Drug Authority Issues: Selected Topics. Food Drug Law J 48:545Google Scholar
  12. 12.
    Izzo U (2006) Danno lungolatente alla persona e decorrenza della prescrizione nell’azione risarcitoria ruolo dell’informazione ed oneri probatori. In: Izzo U (ed) Dialoghi sul danno alla persona. Università degli Studi di Trento, Trento, p 257Google Scholar
  13. 13.
    Izzo U (2004b) La precauzione nella responsabilità civile. Analisi di un concetto sul tema del danno da contagio per via trasfusionale. Cedam, PadovaGoogle Scholar
  14. 14.
    Joerges C, Ladeur K-H, Vos E (eds) (1997) Integrating scientific expertise into regulatory decision-making. National traditions and European innovations. Baden-Baden: Nomos, pp 295–323Google Scholar
  15. 15.
    Khushf G, Wilson R (2006) Symposium article: Introduction a sympathetic but critical assessment of nanotechnology initiatives. J Law Med Ethics 34:655CrossRefGoogle Scholar
  16. 16.
    Kurzweil VR (1999) The age of spiritual machines: when computers exceed human intelligence. Penguim, New YorkGoogle Scholar
  17. 17.
    Lavender M (2005) Regulating innovative medicine: fitting square pegs in round holes. Duke Law Tech Rev 1Google Scholar
  18. 18.
    Lin AC (2006) Size matters: regulating nanotechnology. US Davis Legal Studies Research. Paper 635. http://ssrn.com/abstract=934635. Cited October, 2006
  19. 19.
    Marchetti B (2005) Pubblica amministrazione e corti negli Stati Uniti. Il judicial review sulle administrative agencies. Cedam, PadovaGoogle Scholar
  20. 20.
    Noah B (2004a) Bioethical malpractice: risk and responsibility in human research. J Health Care Law Policy 7:175Google Scholar
  21. 21.
    Noah L (2003b) Challenges in the federal regulation of pain management technologies. J Law Med Ethics 31:55CrossRefGoogle Scholar
  22. 22.
    Pascuzzi G (2006) Il diritto dell’era digitale. Tecnologie informatiche e regole privatistiche. il Mulino, Bologna, p 208Google Scholar
  23. 23.
    Reimann M (2003) Liability for detective products at the beginning of the twenty-first century: emergence of a worldwide standard? Am J Comp Law 51:571Google Scholar
  24. 24.
    Reynolds GH (2003) Nanotechnology and regulatory policy: three futures. Harv J Law Tech 17:179Google Scholar
  25. 25.
    Rodotà S (2006) La vita e le regole Tra diritto e non diritto. Feltrinelli, Milano, p 193Google Scholar
  26. 26.
    Sieff B (2004) Rigenerazione di dispositivi medici e responsabilità – Profili di regolamentazione nella normativa comunitaria ed italiana. Danno e responsabilità, 772Google Scholar
  27. 27.
    Sunstein CR (1996) Health-health tradeoffs. Univ Chic Law Rev 63:1533CrossRefGoogle Scholar
  28. 28.
    Viscusi WK, Harrington JE, Vernon JM (2005) Economics of regulation and antitrust. MIT, CambridgeGoogle Scholar
  29. 29.
    Wynne B (1992) Uncertainty and environmental learning: reconceiving science and policy in the preventive paradigm. Glob Environ Change 111Google Scholar
  30. 30.
    Zhou W (2003) Ethics of nanobiotechnology at the frontline. Santa Clara Comput High-Technol Law J 19:481Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  1. 1.Centro interdipartimentale per le decisioni giuridico-ambientali e la certificazione etica di impresa (CIGA)University of Padova (Italia)RovigoItaly

Personalised recommendations